Last fall, when Dainippon Sumitomo Pharma announced that it had inked a deal to buy Sepracor for $2.6 billion , the Japanese pharma company cited the once-daily epilepsy drug Stedesa as one of the
Sepracor is losing its top executive but not its name in an overhaul following its acquisition by Japan's Dainippon Sumitomo Pharma. Adrian Adams, the company's president and CEO, has stepped down
With the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo drawing to a close soon, the developer's CEO is on his way over to take the helm at Raleigh, NC-based Inspire Pharmaceuticals.
Dainippon Sumitomo has filed for FDA approval of its prospective blockbuster schizophrenia drug lurasidone , beating its own timetable as the Japanese pharma giant stays on course toward an expected
Japan's Dainippon Sumitomo has completed its $2.6 billion deal to buy Sepracor and has set aside a tidy package of $11 million for CEO Adrian Adams ( photo ). The Boston Business Journal checked out
Two of Sepracor's stockholders are shouting foul in a lawsuit aimed at derailing Dainippon Sumitomo's $2.6 billion acquisition pact , hoping for a richer deal in the process. Close to a week ago,
Sepracor shareholders aren't happy. They're so unhappy that management agreed to sell itself to Japan's Dainippon Sumitomo Pharma at $23 per share that they've sued, calling the price unfair and
Marlborough, MA-based Sepracor was quick to reassure the Boston biotech community that Dainippon's $2.6 billion acquisition of the company wouldn't interfere with its local operations. The Japanese
Another Japanese pharma has snapped up a U.S. drugmaker. This time, it's Dainippon Sumitomo Pharma, which will pay $2.6 billion for Sepracor mainly to get access to the latter's sales network.
Spurred by a stagnating home drug market, Japan's Dainippon Sumitomo has struck a deal to buy Sepracor for $2.6 billion. Backed by bridge loans, Dainippon says it will pay $23 a share for Sepracor, a